FDA panel backs Celebrex for juvenile RA

FDA's Arthritis Drugs Advisory Committee voted 15-1 that the risk/benefit ratio of Celebrex celecoxib

Read the full 140 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE